Output details

Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: preliminary safety results from the CHHiP randomised controlled trial.

CHHiP is one of the largest prostate radiotherapy trials worldwide (3,216 patients) comparing differences in acute and late toxicity between hypofractionated high-dose and standard treatment schedules. This study reported that hypofractionated radiotherapy was equally well tolerated as conventionally fractionated treatment. David Dearnaley acted as Chief Investigator, designed the trial and contributed to patient recruitment; Emma Hall (Clinical Trials and Statistics Unit) was Chief Statistician, responsible for trial management and all statistical analyses. Both collaborated on data interpretation and writing the paper. This influential work demonstrates the ICR’s multidisciplinary team approach to research.